BioCentury | Nov 19, 2019

AGR2 and LYPD3 as breast cancer targets

...Phase I testing of the mAbs. The company is seeking partners for clinical development. TARGET/MARKER/PATHWAY: Anterior gradient 2, protein disulphide isomerase family member (AGR2)...
...doi:10.1016/j.celrep.2019.09.032 CONTACT: Donald P. McDonnell, Duke University School of Medicine, Durham, N.C. email: donald.mcdonnell@duke.edu Claire Quang Duke University Anterior gradient 2, protein disulphide isomerase family member (AGR2) Ly6/PLAUR...
Items per page:
1 - 1 of 1